Vincent Ossipow, Ph.D., CFA, is a Partner at the healthcare investment firm of Omega Funds and brings to the Immunic board 23 years of healthcare investment experience in public and private companies. He is member of the Board of Directors of several private and publicly traded life science companies.
Previously, Dr. Ossipow worked as a Partner for Private Equity at Sectoral Asset Management, one of the largest North American healthcare institutional investors. From 2000 to 2006, he was a research fellow at the University of Geneva where he studied the molecular basis of brain function, and acted as Sectoral Asset Management’s Chief Scientific Officer during this period. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a biotech equities-listed investment vehicle.
Dr. Ossipow trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute in Bethesda, MD. He holds a master’s degree in computational sciences, a master’s degree in molecular biology, and a Ph.D. in molecular biology, all from the University of Geneva. Dr. Ossipow holds a CFA (Chartered Financial Analyst) designation from the CFA Institute. He also completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business.
Dr. Ossipow’s work has been published in major journals. He also co-authored the book Monoclonal Antibodies, Methods in Molecular Biology, published in 2014.
Dr. Ossipow has been a member of Immunic’s Board since April 2019. He is chairman of the Nominating and Corporate Governance Committee.